Key Takeaway: The article discusses the long-term safety and effectiveness of arimoclomol for adult and pediatric patients with Niemann-Pick disease type C. This evaluation is part of the US early access program and will be presented at the 22nd Annual WORLD Symposium in February 2026. The findings aim to provide valuable insights into the treatment's impact.
Price reaction · baseline $9.16 (2026-02-03T19:59:00.000Z) · hit during market hours · clean, no other ZVRA news in the window
day 0 close · peak
0%
Market Sentiment Analysis
POSITIVE FACTORS
Long-term safety and effectiveness of arimoclomol are being evaluated.
The study involves both adult and pediatric patients.
The program is part of a recognized annual symposium.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Lead asset
KP415
Phase 3 · ADHD
Full Press Release Details
< Publications and Presentations
Long-term safety and effectiveness of arimoclomol adult and pediatricNiemann-Pick disease type C patients in the US early access program (EAP)
22nd Annual WORLDSymposium - 02/03/2026
Download PDF
Download PDF
Frequently Asked Questions
What is the focus of the arimoclomol study?
The study focuses on the long-term safety and effectiveness of arimoclomol.
Who are the participants in the arimoclomol study?
The study includes both adult and pediatric patients with Niemann-Pick disease type C.
When will the study results be presented?
The findings will be presented at the 22nd Annual WORLD Symposium in February 2026.